Major advancements in artificial intelligence (AI) have attracted billions of dollars in new investment, and the IPO market has taken notice. The percentage of US IPOs referencing AI in their prospectuses has climbed in each of the past six years, and leapt to...read more
The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and...read more
Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for rare diseases, raised $436 million by offering 24.2 million shares at $18, the high end of the range of $16 to $18. The company offered 2.2 million shares than anticipated. It...read more
Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for rare diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Salt Lake City, UT-based company now plans to raise $374 million by offering 22 million...read more
AI is the IPO market's next buzzword
Major advancements in artificial intelligence (AI) have attracted billions of dollars in new investment, and the IPO market has taken notice. The percentage of US IPOs referencing AI in their prospectuses has climbed in each of the past six years, and leapt to...read more
US IPO Weekly Recap: Coinbase’s direct listing headlines a 9 IPO week
The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and...read more
Recursion Pharmaceuticals prices further upsized IPO at $18 high end
Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for rare diseases, raised $436 million by offering 24.2 million shares at $18, the high end of the range of $16 to $18. The company offered 2.2 million shares than anticipated. It...read more
Recursion Pharmaceuticals ups share offering by 22% ahead of $374 million IPO
Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for rare diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Salt Lake City, UT-based company now plans to raise $374 million by offering 22 million...read more